Activity: Membership types › Membership of network
The Radiotherapy (RT)- Drug Combinations Working Group (WG) is a national effort to coordinate a research framework for RT-Drug Combinations, encompassing discovery science, biomarker development and translation into clinical trials. The WG has been established by the Cancer Research UK (CRUK) RadNet network and has been ratified by the CRUK RadNet Steering Board as having an essential remit to further RT-Drug Combination research on behalf of the network.
The WG will focus mainly on discovery and preclinical science covering all activity up to Phase I trials, with collaboration with other stakeholders including CTRad for clinical translation. The WG is a forum for sharing scientific expertise, clinical knowledge and best practice whilst avoiding duplication. Other opportunities include holding specific workshops or advisory panel sessions through partnership with Pharma and relevant societies.
Working Groups are not directly funded by CRUK, therefore obtaining funding will be key to progressing WG projects or objectives.
1 Jan 2021 → 31 Dec 2023
CRUK RadNet Radiotherapy-Drug Combination Working Group, United Kingdom